Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
August 08 2022 - 4:05PM
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage,
precision-oncology biopharmaceutical company, today announced
Company’s second quarter 2022 financial results will be released on
Monday, August 15, 2022. Company management will host a conference
call on Monday, August 15, 2022, at 2:00 p.m. Pacific Time / 5:00
p.m. Eastern Time to discuss the financial results and other recent
corporate highlights.
Participants who wish to join the conference call
by telephone can use this link to register and receive the dial-in
numbers and unique PIN to access the call. The conference call
registration and live audio webcast can be accessed via the
Investors section of the Company’s website at www.calithera.com.
Please log in approximately 5-10 minutes before the event to ensure
a timely connection. The archived webcast will remain available for
replay on Calithera’s website for 30 days.
About Calithera
Calithera Biosciences is a clinical-stage,
precision oncology biopharmaceutical company developing targeted
therapies to redefine treatment for biomarker-specific patient
populations. Driven by a commitment to rigorous science and a
passion for improving the lives of people impacted by cancer and
other life-threatening diseases, Calithera is advancing a robust
pipeline of investigational, small-molecule oncology compounds with
a biomarker-driven approach that targets genetic vulnerabilities in
cancer cells to deliver new therapies for patients suffering from
aggressive hematologic and solid tumor cancers for which there are
currently limited treatment options.
Calithera is headquartered in South San Francisco,
California. For more information about Calithera, please visit
www.calithera.com.
Forward Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as "may,"
"will," "expect," "anticipate," "estimate," "intend," "poised" and
similar expressions (as well as other words or expressions
referencing future events, conditions, or circumstances) are
intended to identify forward-looking statements. These statements
include those related to the safety, tolerability and efficacy of
Calithera’s product candidates, the overall advancement of
Calithera’s product candidates in preclinical development and
clinical trials, the unmet need in the treatment of patients with
advanced disease, and Calithera’s plans to continue development of
its product candidates. Because such statements are subject to
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. The
potential product candidates that Calithera develops may not
progress through clinical development or receive required
regulatory approvals within expected timelines or at all. In
addition, clinical trials may not confirm any safety, potency or
other product characteristics described or assumed in this press
release. Such product candidates may not be beneficial to patients
or be successfully commercialized. The failure to meet expectations
with respect to any of the foregoing matters may have a negative
effect on Calithera's stock price. Additional information
concerning these and other risk factors affecting Calithera's
business can be found in Calithera's periodic filings with the
Securities and Exchange Commission at www.sec.gov. These
forward-looking statements are not guarantees of future performance
and speak only as of the date hereof, and, except as required by
law, Calithera disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.
CONTACTS:Stephanie Wong
ir@Calithera.com650.870.1063
INVESTORS:Burns McClellanLee
Roth212.213.0006lroth@burnsmc.com
MEDIA:Sam Brown, Inc.Hannah
Hurdle805.338.4752hannahhurdle@sambrown.com
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Nov 2024 to Dec 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Dec 2023 to Dec 2024